ProSci

TIGIT Detection Set (Risk Free)

Product Code:
 
PSI-RF16050
Product Group:
 
Antibody Detection Sets
Supplier:
 
ProSci
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1, IgG2a, IgG2b
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
See Set Contents
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunocytochemistry (ICC)
  • Immunofluorescence (IF)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
Shipping:
 
blue ice
Storage:
 
Antibodies can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-RF16050-1Set1Set£447.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Background:
The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2). ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications
Background References:
  • Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63.
  • Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37.
Buffer:
PBS containing 0.02% sodium azide.
Concentration:
Antibody 1 mg/mL
Conjugate:
Unconjugated
Immunogen:
TIGIT antibodies were raised against the extracellular domain of human TIGIT.
Physical State:
Liquid
Purification:
Antibodies are supplied as protein A purified IgG2b.
Set Contents:
TIGIT Antibody [7E5], Cat. No. RF16051 (20 μg)

TIGIT Antibody [3B5], Cat. No. RF16053 (20 μg)

TIGIT Antibody [4A10], Cat. No. RF16054 (20 μg)

TIGIT Antibody [4A11], Cat. No. RF16055 (20 μg)

TIGIT Antibody [4A12], Cat. No. RF16056 (20 μg)

TIGIT Antibody [10B1], Cat. No. RF16058 (20 μg)
User Note:
Optimal dilutions for each application to be determined by the researcher.

Documents

References

  1. Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63.
  2. Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37.